Description

Book Synopsis


Trade Review
Malignant is punchy and persuasive, and the author is clearly in command of his subject matter. Prasad offers valuable advice on how to keep up with research as well as the appropriate way to analyse clinical trial reports.
—Talha K Burki, The Lancet Hematology
Aimed at general readers (including patients), oncology trainees and experts in health-care policy, it informs and disturbs throughout.
—Andrew Robinson, Nature
Patients should ask their oncologist how good the cure is: do I really live longer and better than doing "nothing"? Let them start by asking whether their doctor has read Prasad's book.
—Zurich Weekly News Review
[Malignant is] so applicable to the issues of the pandemic . . . Because what we're seeing is a research infrastructure that is not set up to do rapid evaluation, and to be resilient and to respond to a health crisis.
—Marty Makary, MD, MPH, MedPage Today

Table of Contents

Acknowledgments
Introduction

Part I. Cancer Drugs: The Outcomes They Improve and at What Price
Chapter 1. The Basics of Cancer Drugs: Cost, Benefit, Value
Chapter 2. Surrogate Endpoints in Cancer: What Are They and Where Are They Used?
Chapter 3. The Use and Misuse of Surrogate Endpoints for Drug Approvals
Chapter 4. How High Prices Harm Patients and Society

Part II. Societal Forces That Distort Cancer Medicine
Chapter 5. Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine
Chapter 6. Financial Conflict of Interest
Chapter 7. The Harms of Financial Conflicts and How to Rehabilitate Medicine
Chapter 8. Will Precision Oncology Save Us?

Part III. How to Interpret Cancer Evidence and Trials
Chapter 9. Study Design 201
Chapter 10. Principles of Oncology Practice
Chapter 11. Important Trials in Oncology
Chapter 12. Global Oncology

Part IV. Solutions
Chapter 13. How Should Cancer Drug Development Proceed?
Chapter 14. What Can Three Federal Agencies Do Tomorrow?
Chapter 15. What Can People with Cancer Do?
Chapter 16. What Can Students, Residents, and Fellows Do?

Epilogue: The Hallmarks of Successful Cancer Policy
Glossary
References
Index

Malignant

    Product form

    £26.10

    Includes FREE delivery

    RRP £29.00 – you save £2.90 (10%)

    Order before 4pm today for delivery by Wed 1 Jul 2026.

    A Hardback by Vinayak K. Prasad

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of Malignant by Vinayak K. Prasad

      Publisher: Johns Hopkins University Press
      Publication Date: 21/04/2020
      ISBN13: 9781421437637, 978-1421437637
      ISBN10: 1421437635
      Also in:
      Education Law Public health and safety law Medical ethics and professional conduct Medicolegal issues

      Description

      Book Synopsis


      Trade Review
      Malignant is punchy and persuasive, and the author is clearly in command of his subject matter. Prasad offers valuable advice on how to keep up with research as well as the appropriate way to analyse clinical trial reports.
      —Talha K Burki, The Lancet Hematology
      Aimed at general readers (including patients), oncology trainees and experts in health-care policy, it informs and disturbs throughout.
      —Andrew Robinson, Nature
      Patients should ask their oncologist how good the cure is: do I really live longer and better than doing "nothing"? Let them start by asking whether their doctor has read Prasad's book.
      —Zurich Weekly News Review
      [Malignant is] so applicable to the issues of the pandemic . . . Because what we're seeing is a research infrastructure that is not set up to do rapid evaluation, and to be resilient and to respond to a health crisis.
      —Marty Makary, MD, MPH, MedPage Today

      Table of Contents

      Acknowledgments
      Introduction

      Part I. Cancer Drugs: The Outcomes They Improve and at What Price
      Chapter 1. The Basics of Cancer Drugs: Cost, Benefit, Value
      Chapter 2. Surrogate Endpoints in Cancer: What Are They and Where Are They Used?
      Chapter 3. The Use and Misuse of Surrogate Endpoints for Drug Approvals
      Chapter 4. How High Prices Harm Patients and Society

      Part II. Societal Forces That Distort Cancer Medicine
      Chapter 5. Hype, Spin, and the Unbridled Enthusiasm That Distorts Cancer Medicine
      Chapter 6. Financial Conflict of Interest
      Chapter 7. The Harms of Financial Conflicts and How to Rehabilitate Medicine
      Chapter 8. Will Precision Oncology Save Us?

      Part III. How to Interpret Cancer Evidence and Trials
      Chapter 9. Study Design 201
      Chapter 10. Principles of Oncology Practice
      Chapter 11. Important Trials in Oncology
      Chapter 12. Global Oncology

      Part IV. Solutions
      Chapter 13. How Should Cancer Drug Development Proceed?
      Chapter 14. What Can Three Federal Agencies Do Tomorrow?
      Chapter 15. What Can People with Cancer Do?
      Chapter 16. What Can Students, Residents, and Fellows Do?

      Epilogue: The Hallmarks of Successful Cancer Policy
      Glossary
      References
      Index

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account